tbuckley/cabot-search huggingface dataset:
COVID-19 in Adults With Congenital Heart Disease
Authors: Craig S. Broberg, Adrienne H. Kovacs, Soraya Sadeghi, Marlon S. Rosenbaum, Matthew J. Lewis, Matthew R. Carazo, Fred H. Rodriguez, Dan G. Halpern, Jodi Feinberg, Francisca Arancibia Galilea, Fernando Baraona, Ari M. Cedars, Jong M. Ko, Prashob Porayette, Jennifer Maldonado, Berardo Sarubbi, Flavia Fusco, Alexandra A. Frogoudaki, Amiram Nir, Anisa Chaudhry, Anitha S. John, Arsha Karbassi, Arvind K. Hoskoppal, Benjamin P. Frischhertz, Benjamin Hendrickson, Berto J. Bouma, Carla P. Rodriguez-Monserrate, Christopher R. Broda, Daniel Tobler, David Gregg, Efren Martinez-Quintana, Elizabeth Yeung, Eric V. Krieger, Francisco J. Ruperti-Repilado, George Giannakoulas, George K. Lui, Georges Ephrem, Harsimran S. Singh, Hassan MK. Almeneisi, Heather L. Bartlett, Ian Lindsay, Jasmine Grewal, Jeremy Nicolarsen, John J. Araujo, Jonathan W. Cramer, Judith Bouchardy, Khalid Al Najashi, Kristi Ryan, Laith Alshawabkeh, Lauren Andrade, Magalie Ladouceur, Markus Schwerzmann, Matthias Greutmann, Pablo Meras, Paolo Ferrero, Payam Dehghani, Poyee P. Tung, Rocio Garcia-Orta, Rose O. Tompkins, Salwa M. Gendi, Scott Cohen, Scott Klewer, Sebastien Hascoet, Shabnam Mohammadzadeh, Shailendra Upadhyay, Stacy D. Fisher, Stephen Cook, Timothy B. Cotts, Jamil A. Aboulhosn
Journal: Journal of the American College of Cardiology (2021)
The potential of artificial intelligence to improve patient safety: a scoping review
Authors: David W. Bates, David Levine, Ania Syrowatka, Masha Kuznetsova, Kelly Jean Thomas Craig, Angela Rui, Gretchen Purcell Jackson, Kyu Rhee
Journal: npj Digital Medicine (2021)

Abstract Artificial intelligence (AI) represents a valuable tool that could be used to improve the safety of care. Major adverse events in healthcare include: healthcare-associated infections, adverse drug events, venous thromboembolism, surgical complications, pressure ulcers, falls, decompensation, and diagnostic errors. The objective of this scoping review was to summarize the relevant literature and evaluate the potential of AI to improve patient safety in these eight harm domains. A structured search was used to query MEDLINE for relevant articles. The scoping review identified studies that described the application of AI for prediction, prevention, or early detection of adverse events in each of the harm domains. The AI literature was narratively synthesized for each domain, and findings were considered in the context of incidence, cost, and preventability to make projections about the likelihood of AI improving safety. Three-hundred and ninety-two studies were included in the scoping review. The literature provided numerous examples of how AI has been applied within each of the eight harm domains using various techniques. The most common novel data were collected using different types of sensing technologies: vital sign monitoring, wearables, pressure sensors, and computer vision. There are significant opportunities to leverage AI and novel data sources to reduce the frequency of harm across all domains. We expect AI to have the greatest impact in areas where current strategies are not effective, and integration and complex analysis of novel, unstructured data are necessary to make accurate predictions; this applies specifically to adverse drug events, decompensation, and diagnostic errors.
Recent Progress of Alkyl Radicals Generation‐Based Agents for Biomedical Applications
Authors: Ka‐Wai Lee, Yingpeng Wan, Xiaozhen Li, Xiao Cui, Shengliang Li, Chun‐Sing Lee
Journal: Advanced Healthcare Materials (2021)

Abstract Photodynamic therapy (PDT) is extensively explored for anticancer and antibacterial applications. It typically relies on oxygen‐dependent generation of reactive oxygen species (ROS) to realize its killing effect. This type of therapy modality shows compromised therapeutic results for treating hypoxic tumors or bacteria‐infected wounds. Recently, alkyl radicals attracted much attention as they can be generated from some azo‐based initiators only under mild heat stimulus without oxygen participation. Many nanocarriers or hydrogel systems have been developed to load and deliver these radical initiators to lesion sites for theranostics. These systems show good anticancer or antimicrobial effect in hypoxic environment and some of them possess specific imaging abilities providing precise guidance for treatment. This review summarizes the developed materials that aim at treating hypoxic cancer and bacteria‐infected wound by using this kind of oxygen‐irrelevant alkyl radicals. Based on the carrier components, these agents are divided into three groups: inorganic, organic, as well as inorganic and organic hybrid carrier‐based therapeutic systems. The construction of these agents and their specific advantages in biomedical field are highlighted. Finally, the existing problems and future promising development directions are discussed.
Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials
Authors: Lesley A Stewart, Mark Simmonds, Lelia Duley, Alexis Llewellyn, Sahar Sharif, Ruth AE Walker, Lucy Beresford, Kath Wright, Mona M Aboulghar, Zarko Alfirevic, Azam Azargoon, Rashmi Bagga, Elham Bahrami, Sean C Blackwell, Steve N Caritis, C Andrew Combs, Jennifer M Croswell, Caroline A Crowther, Anita F Das, Kay Dickersin, Kristina C Dietz, Andrew Elimian, William A Grobman, Alexander Hodkinson, Kimberley A Maurel, David S McKenna, Ben W Mol, Kelle Moley, Jamie Mueller, Anwar Nassar, Jane E Norman, John Norrie, John M O'Brien, Raphael Porcher, Shalini Rajaram, Line Rode, Dwight J Rouse, Carol Sakala, Ewoud Schuit, Marie-Victoire Senat, Sahar Sharif, Mark Simmonds, Joe L Simpson, Katherine Smith, Anne Tabor, Elizabeth A Thom, Melanie A van Os, Evelyn P Whitlock, Stephen Wood, Tom Walley
Journal: The Lancet (2021)
P02.23 Robotic Thoracic Surgery - A Comparison of Age-Groups Outcomes.
Authors: R. Haddad, R. Terra, J. Campos, F. Braga, C. Lima, P. De Araujo, B. Bibas, L. Lauricella, R. Souza, P. Pêgo-Fernandes, J. Trindade
Journal: Journal of Thoracic Oncology (2021)
Increased expression of MARCKS in cancer cells represents a potential target for treatment
Authors: Ju–hyung Woo, Kathleen Wilsbach, Albert Nordin, Annaka Lorincz, Edward Gabrielson
Journal: Cancer Research (2004)

5149  Using in vitro phosphorylation reactions, we discovered that the myristoylated alanine-rich C-kinase substrate (MARCKS) is substrate for the G1 kinases, cdk4/6, as well as for protein kinase C (PKC). Thus, this substrate appears to link PKC signal transduction pathways and cell-cycle signaling. Although MARCKS has previously been implicated as a potential tumor suppressor gene, we found significantly increased levels of MARCKS expression in many cell lines and primary tumor samples from breast and lung cancers, including small cell and non-small cell varieties. This increased expression is not accompanied by mutations of MARCKS, leading us to consider activation of a MARCKS pathway as a contributor to the cancer phenotype. To understand the function of MARCKS in this setting, we introduced MARCKS targeted siRNA into replicating cultures of MDA-361 and MCF-7 breast cancer cells. This led to a dose- and time-dependent decrease in MARCKS expression, increased expression of p27 (as measured by immunoblot), and dramatic inhibition of cell growth. Together, these results suggest that MARCKS has a critical, and complex, signaling function in cancer cells. Many cancers have increased expression of MARCKS, and this might represent a novel target for cancer treatment.
P76.16 EGFR-L858R NSCLC with Pleiotropic Resistance Mechanisms: T790M, C797S, SCLC-Transformation and KRAS, TP53, and BRAF Mutations.
Authors: E. Urbanska, J. Soerensen, L. Melchior, E. Santoni-Rugiu
Journal: Journal of Thoracic Oncology (2021)
P35.07 Analysis of Inter-Tumor Heterogeneity Among Lesions in Autopsy Cases With Untreated Lung Cancer by DNA Methylation Profiling
Authors: H. Harada, K. Yagyu, M. Nishida, A. Kamigaichi, K. Miyazaki, Y. Nishimura, K. Kawaguchi, Y. Matsumoto, K. Hirano, S. Shibata
Journal: Journal of Thoracic Oncology (2021)
In regard to Sahebjam et al.
Authors: Sezin Yuce Sari, Gozde Yazici
Journal: Neuro-Oncology (2020)

Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study" by Sahebjam et al. with great interest. 1We have also been studying this subject for a while.We congratulate the authors for being the first to publish the results of concurrent stereotactic radiotherapy (SRT) and immune checkpoint inhibitors (ICI) for recurrent high-grade gliomas.This study will surely lead us in this field.However, the study has some conflicting points.First of all, the authors compared the control, overall survival (OS), and progression-free survival (PFS) rates in bevacizumab-naive and -resistant patients.We would also like to know the respective rates in the whole population.Besides, the 6-and 12-month PFS rates and 24-month OS were not given for bevacizumab-resistant patients.Is that because these rates are 0%?We also think there may be a mistake in follow-up durations.Median follow-up was reported 3.7 months and 3.1 months for bevacizumab-naive and -resistant patients, respectively.However, survival rates up to 2 years were given.We think that the most striking finding of this study would be the detailed progression pattern.However, there are many unknown data on this.Did all patients receive 5 cycles of treatment?The authors stated that the medications were stopped due to disease progression in 22 patients (66%), but in Table 3, only two patients seem to progress.We assume this indicates local progression.If so, where did the other patients progress?Then, what does the "disease control" rate stand for in Table 3?If it is local progression, then it should not be 75% for bevacizumab-resistant patients.And if all naive patients were under control, what is the reason for those OS and PFS rates?What does the term "best" overall response indicate in the heading of Table 3? Maybe, all the incomprehensible results are hidden in that word.We would like the authors to detail these findings.Also, this recurrence was second in 13 patients and even third in 1 patient.What did these patients receive in prior treatments?And how many had used ICI before?Because the authors state 1 patient progressed on nivolumab.We think that after these questions are replied, this study can give us more information about the future of ICI combined with SRT in recurrent high-grade gliomas.
Outcomes for Patients Following Hospitalization for COVID-19
Authors: Hallie C. Prescott
Journal: JAMA (2021)

The Writing Committee for the COMEBAC Study Group; Luc Morin, MD, MSc; Laurent Savale, MD, PhD; Tài Pham, MD, PhD; Romain Colle, MD, PhD; Samy Figueiredo, MD, PhD; Anatole Harrois, MD, PhD; Matthieu Gasnier, MD; Anne-Lise Lecoq, MD, PhD; Olivier Meyrignac, MD, PhD; Nicolas Noel, MD, PhD; Elodie Baudry, MD; Marie-France Bellin, MD; Antoine Beurnier, MD; Walid Choucha, MD; Emmanuelle Corruble, MD, PhD; Laurent Dortet, PharmD, PhD; Isabelle Hardy-Leger, MA; François Radiguer, MA; Sabine Sportouch, MA; Christiane Verny, MD; Benjamin Wyplosz, MD, PhD; Mohamad Zaidan, MD, PhD; Laurent Becquemont, MD, PhD; David Montani, MD, PhD; Xavier Monnet, MD, PhD
Response by Mital et al to Letter Regarding Article, “A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy”
Authors: Seema Mital, Katey R. Armstrong, Ryan J. Butts, Jennifer Conway, Steve Fan, Letizia Gardin, Paul F. Kantor, Beth Kaufman, Myriam Lafreniere-Roula, Anastasia Miron, Marc E. Richmond, Joseph W. Rossano, Mark W. Russell, Chet Villa, Robert G. Weintraub
Journal: Circulation (2021)
Pediatric tri-tube valved conduits made from fibroblast-produced extracellular matrix evaluated over 52 weeks in growing lambs
Authors: Zeeshan H. Syedain, Bee Haynie, Sandra L. Johnson, Matthew Lahti, James Berry, John P. Carney, Jirong Li, Ryan C. Hill, Kirk C. Hansen, Greeshma Thrivikraman, Richard Bianco, Robert T. Tranquillo
Journal: Science Translational Medicine (2021)

A pulmonary replacement valve made from three tubes of cell-derived matrix functioned for 52 weeks in lambs and calcified less than commercial valves.
Clare Gerada: Tackling intersectionality must be our post-covid legacy
Authors: Clare Gerada
Journal: BMJ (2021)

Plastic bronchitis is a rare, underdiagnosed and potentially fatal condition. It is characterised by the formation and expectoration of branching gelatinous plugs that assume the shape of the airways. These airway plugs differ from the allergic mucin that characterises allergic bronchopulmonary aspergillosis and mucoid impaction of the bronchi. Plastic bronchitis is most often encountered in the paediatric population following corrective cardiac surgery, such as the Fontan procedure. It also occurs in adults. Plastic bronchitis in adults is rare, heterogeneous in its aetiology, and can lead to respiratory distress or even life-threatening airway obstruction. Plastic bronchitis in adulthood should not be overlooked, particularly in patients with chronic inflammatory lung diseases. This review presents current understanding of the presentation, aetiology, pathogenesis, pathology and management of plastic bronchitis in adults.
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
Authors: Jocelyn Keehner, Lucy E Horton, Michael A Pfeffer, Christopher A Longhurst, Robert T Schooley, Judith S Currier, Shira R Abeles, Francesca J Torriani
Journal: New England Journal of Medicine (2021)

SARS-CoV-2 Vaccine and Infection in Health Workers After more than 36,500 health care workers at the University of California received at least one dose of vaccine, 71% of 379 workers with positive...
P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study
Authors: V.D. Haakensen, H. Horndalsveen, H.M. Nymoen, G. Holgersson, L. Holm Land, J. Koivunen, S. Cicenas, K. Oselin, T. Madebo, R. Van Helvoirt, N. Helbekkmo, B.H. Grønberg, M. Aanerud, L. Rogg, Å. Helland
Journal: Journal of Thoracic Oncology (2021)
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Authors: Aakash Desai, Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta Pal, Stephen V. Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, Tomislav Dragovich, Marc Matrana, Neeraj Agarwal, Sant Chawla, Shumei Kato, Gilberto Morgan, Pashtoon M. Kasi, Benjamin Solomon, Herbert H. Loong, Haeseong Park, Toni K. Choueiri, Ishwaria M. Subbiah, Naveen Pemmaraju, Vivek Subbiah
Journal: Nature Reviews Clinical Oncology (2021)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Authors: Joaquim Bellmunt, Maha Hussain, Jürgen E Gschwend, Peter Albers, Stephane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H O'Donnell, Jonathan E Rosenberg, Daniel M Geynisman, Daniel P Petrylak, Jean Hoffman-Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S van der Heijden, Cora N Sternberg, Nicole N Davarpanah, Thomas Powles
Journal: The Lancet Oncology (2021)
The interaction of cognitive and brain reserve with frailty in the association with mortality: an observational cohort study
Authors: Jendé L Zijlmans, Sander Lamballais, Lies Lahousse, Meike W Vernooij, M Kamran Ikram, M Arfan Ikram, Annemarie I Luik
Journal: The Lancet Healthy Longevity (2021)

A higher cognitive reserve and brain reserve could decrease mortality risk, but the interaction of these factors with general age-related loss of physical fitness (eg, frailty) remains unclear with regards to mortality. We investigated the associations of cognitive and brain reserve with mortality and the interaction of cognitive and brain reserve with frailty within these associations.Within the observational population-based cohort of the Rotterdam Study, we included participants who visited the research centre for a cognitive assessment between March 2, 2009, and March 1, 2012. Participants with an incomplete assessment of cognition, no data on education attainment, no MRI or an MRI of insufficient quality, three or more missing frailty criteria, or a dementia diagnosis were excluded. Participants were followed up until their death or May 1, 2019. Cognitive reserve was defined as a latent variable that captures variance across five cognitive tests. Brain reserve was defined as the proportion of healthy-appearing brain volume relative to total intracranial volume measured with 1·5 Tesla MRI. Frailty was defined according to Fried's frailty phenotype; participants meeting at least one of the five criteria were considered frail. Hazard ratios (HRs) for associations of cognitive reserve, brain reserve, frailty, and reserve-frailty interactions with the risk of mortality were estimated using Cox regression models.2878 individuals in the Rotterdam Study who visited the research centre for a cognitive assessment were considered eligible. 1388 individuals were excluded due to incomplete or missing data or a dementia diagnosis. 1490 participants with valid information on cognitive reserve, brain reserve, and frailty were included (mean age 74·3 years [SD 5·5]; 815 [55%] female participants). 810 (54%) participants were classified as frail. A higher cognitive reserve (HR 0·87 per SD, 95% CI 0·76-0·99, p=0·036) and a higher brain reserve (0·85 per SD, 0·72-1·00, p=0·048) were associated with a lower risk of mortality, after adjusting for sex, age, educational level, body-mass index, smoking status, and number of comorbidities. The association between cognitive reserve and mortality was more pronounced (0·77 per SD, 0·66-0·90, p=0·0012) when the cognitive reserve-frailty interaction (p=0·0078) was included, indicating that higher cognitive reserve is related to lower mortality in individuals with frailty. The brain reserve-frailty interaction was non-significant.Higher cognitive reserve and higher brain reserve were associated with a lower mortality risk. Additionally, cognitive reserve and frailty interact in the association with mortality, such that higher cognitive reserve is particularly associated with lower mortality in frail participants.Netherlands Organization for Health Research and Development and EU Horizon 2020 research programme.
Publisher Correction: Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes
Authors: Evgeny Kiner, Elijah Willie, Brinda Vijaykumar, Kaitavjeet Chowdhary, Hugo Schmutz, Jodie Chandler, Alexandra Schnell, Pratiksha I. Thakore, Graham LeGros, Sara Mostafavi, Diane Mathis, Christophe Benoist
Journal: Nature Immunology (2021)
Abstract 14323: Impact of One Tibial Artery Revascularization on Skin Perfusion Pressure and Microcirculation in Critically Ischemic Limbs
Authors: Osami Kawarada, Miyuki Noguchi, Shingo Sakamoto, Koichiro Harada, Masaharu Ishihara, Satoshi Yasuda, Hisao Ogawa
Journal: Circulation (2013)

Objectives: Skin perfusion pressure (SPP) can be used to evaluate the microcirculation in the foot. The aim of this study was to clarify the effect of one tibial artery revascularization on the dor...
FP01.03 Genetic Predisposition for Pre-Invasive Lung Adenocarcinoma Manifesting as Ground-Glass Nodules with Family History of Lung Cancer
Authors: R. Fu, J. Zhang, R. Chen, Z. Tai, H. Lin, J. Su, X. Chu, C. Zhang, W. Tang, J. Lin, Q. Nie, X. Yang, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2021)
P76.53 Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors
Authors: T. Ono, S. Igawa, K. Yamada, A. Kameda, A. Oguri, H. Yamamoto, H. Manabe, T. Ozawa, S. Kusuhara, M. Kasajima, M. Kakegawa, S. Otani, T. Fukui, J. Sasaki, K. Naoki
Journal: Journal of Thoracic Oncology (2021)
P28.03 An Autoethnographic Study Exploring the Role of the Lung Cancer Nurse Specialist in the National Optimal Lung Cancer Pathway
Authors: A. Bobat, V. Anderson, N. Barnett, V. Beattie, L. Bostock, K. Clayton, T. Cole, H. Foreman, S. Holden, S. Kefyalew, G. Overton, J. Roberts, J. Ross, P. Shepherd, E. Smerdon, M. Ward
Journal: Journal of Thoracic Oncology (2021)
P86.15 Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan
Authors: G. Chang, J. Shih, H. Chao, C. Yang, C. Lin, J. Hung, S. Hsiao, C. Wang, C. Chian, T. Hsia, C. Yu, Y. Chen
Journal: Journal of Thoracic Oncology (2021)
Cardiac Rehabilitation for Patients With Heart Failure
Authors: Biykem Bozkurt, Gregg C. Fonarow, Lee R. Goldberg, Maya Guglin, Richard A. Josephson, Daniel E. Forman, Grace Lin, JoAnn Lindenfeld, Chris O’Connor, Gurusher Panjrath, Ileana L. Piña, Tina Shah, Shashank S. Sinha, Eugene Wolfel
Journal: Journal of the American College of Cardiology (2021)
P38.08 Clinical Features and Survival Risk Factors of Lung Lymphoepithelioma-Like Carcinoma Based on the SEER Database Analysis
Authors: L. Huang, H. Chen, X. Li, G. Lan, Z. Zhai, Y. Zhu, K. Du, W. Wang, C. Xu, M. Fang
Journal: Journal of Thoracic Oncology (2021)
Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia
Authors: Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sung-Hyun Kim, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim
Journal: Blood (2017)
Signatures of antagonistic pleiotropy in a bacterial flagellin epitope
Authors: Katarzyna Parys, Nicholas R. Colaianni, Ho-Seok Lee, Ulrich Hohmann, Natalie Edelbacher, Alen Trgovcevic, Zuzana Blahovska, Duhwa Lee, Alexander Mechtler, Zsuzsanna Muhari-Portik, Mathias Madalinski, Niklas Schandry, Isaac Rodríguez-Arévalo, Claude Becker, Elisabeth Sonnleitner, Arthur Korte, Udo Bläsi, Niko Geldner, Michael Hothorn, Corbin D. Jones, Jeffery L. Dangl, Youssef Belkhadir
Journal: Cell Host & Microbe (2021)
Role of serotonin receptor signaling in cancer cells and anti-tumor immunity
Authors: Surojit Karmakar, Girdhari Lal
Journal: Theranostics (2021)

Serotonin or 5-hydroxytryptamine (5-HT) is a neurotransmitter known to affect emotion, behavior, and cognition, and its effects are mostly studied in neurological diseases. The crosstalk between the immune cells and the nervous system through serotonin and its receptors (5-HTRs) in the tumor microenvironment and the secondary lymphoid organs are known to affect cancer pathogenesis. However, the molecular mechanism of - alteration in the phenotype and function of - innate and adaptive immune cells by serotonin is not well explored. In this review, we discuss how serotonin and serotonin receptors modulate the phenotype and function of various immune cells, and how the 5-HT-5-HTR axis modulates antitumor immunity. Understanding how 5-HT and immune signaling are involved in tumor immunity could help improve therapeutic strategies to control cancer progression and metastasis.
Tuberculosis — United States, 2020
Authors: Molly Deutsch-Feldman, Robert H. Pratt, Sandy F. Price, Clarisse A. Tsang, Julie L. Self
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

CDC.Among these reports, <5% of the data were missing, providing further confidence that they were reasonably complete.Provisional data were used to calculate national-and state-level TB case counts.Midyear U.S. Census Bureau population estimates § were used for calculating national-and state-level TB § https://www.census.gov/data/tables/time-series/demo/popest/2010s-nationaltotal.html
P02.25 Coexistence of Invasive Adenocarcinoma, Minimally Invasive Adenocarcinoma and Atypical Adenomatous Hyperplasia: A Case Report
Authors: K. Ma, Y. Xu, J. Song, X. Wang, C. Sun, Y. Guo, S. Qiu, Y. Cai, G. Shao, Z. Yang, Y. Liu, P. Zhang
Journal: Journal of Thoracic Oncology (2021)